Buscar
Cyclerion Therapeutics Inc
CYCNAñadir a la lista de seguimiento
3.440USD
-0.060-1.71%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
14.59MCap. mercado
PérdidaP/E TTM
Más Datos de Cyclerion Therapeutics Inc Compañía
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Información de Cyclerion Therapeutics Inc
Símbolo de cotizaciónCYCN
Nombre de la empresaCyclerion Therapeutics Inc
Fecha de salida a bolsaMar 18, 2019
Director ejecutivoGraul (Regina M)
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 18
Dirección301 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono16176217722
Sitio Webhttps://www.cyclerion.com/
Símbolo de cotizaciónCYCN
Fecha de salida a bolsaMar 18, 2019
Director ejecutivoGraul (Regina M)
Ejecutivos de Cyclerion Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
910.24K
+38.57%
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
910.24K
+38.57%
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
--
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cyclerion Therapeutics Inc?
Los cinco principales accionistas de Cyclerion Therapeutics Inc son: Dr. Peter M. Hecht, Ph.D.
¿Cuántas instituciones poseen acciones de Cyclerion Therapeutics Inc (CYCN)?
A fecha de 2026Q1, 37 instituciones poseen acciones de Cyclerion Therapeutics Inc, con un valor de mercado combinado de aproximadamente 318.08K, lo que representa el 7.35% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -667233.00.